




RealRate

PHARMACEUTICAL 2022

Altimmune Inc
Rank 132 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Altimune Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimune Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Altimune Inc is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 357%, being 82% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	204,126
Cost of Goods Sold	0
Intangible Assets	12,419
Liabilities, Current	18,276
Liabilities, Non-Current	0
Other Assets	872
Other Compr. Net Income	4.4
Other Expenses	11,370
Other Liabilities	1,454
Other Net Income	-177
Other Revenues	4,410
Property and Equipment	1,448
Research and Development	74,541
Selling, General and Administrative Expense	15,413

Output Variable	Value in 1000 USD
Assets	218,865
Liabilities	19,730
Expenses	101,324
Revenues	4,410
Stockholders Equity	199,135
Net Income	-97,091
Comprehensive Net Income	-97,089
BaseVar	172,255
ECR before Limited Liability	283%
Economic Capital Ratio	357%